WellCare Merges with Centene for $17.3 Billion

We represented WellCare Health Plans, Inc. in its merger with Centene Corporation (NYSE: CNC) for $17.3 billion. The combined company will serve more than 24 million members in all 50 states and will be headquartered in St. Louis, Missouri, though it will still maintain operations in Tampa, Florida, where WellCare is currently headquartered.

The transaction was highlighted in several media outlets, including:

This transaction was named a winner in the following two categories for the 19th Annual M&A Advisor Awards in 2020: “Healthcare and Life Sciences Deal of the Year (Over $1B)” and “Corporate/Strategic Deal of the Year (Over $1B).”

Centene Corporation (NYSE: CNC) is a diversified, multi-national healthcare enterprise that provides a portfolio of services to government-sponsored and commercial healthcare programs, focusing on under-insured and uninsured individuals.

WellCare Health Plans, Inc. (Formerly NYSE: WCG) focuses primarily on providing government-sponsored managed care services to families, children, seniors and individuals with complex medical needs primarily through Medicaid, Medicare Advantage and Medicare Prescription Drug Plans, as well as individuals in the Health Insurance Marketplace.

You Also May Be Interested In:

  • Representation of Parthenon Capital, a growth-oriented private equity firm, as healthcare regulatory counsel in its investment in RxSense, a high-growth healthcare technology company that utilizes its proprietary technology platform to provide innovative prescription savings solutions to consumers and pharmacy benefits administration and analytics to enterprise customers

    We served as healthcare regulatory counsel to Parthenon Capital, a growth-oriented private equity firm, in its investment in RxSense, a...
    Client Type: Private Company
  • Lead Counsel to POINT Biopharma Inc. in connection with its proposed SPAC business combination with Therapeutics Acquisition Corp. d/b/a Research Alliance Corp. I (Nasdaq: RACA), a special purpose acquisition company, sponsored by RA Capital Management.  Upon closing, the combined company will be named POINT Biopharma Global Inc. and is expected to be listed on Nasdaq under the ticker symbol “PNT”.

    We served as lead legal counsel to POINT Biopharma Inc., a late stage biopharmaceutical company dedicated to bringing the many...
    Client Type: Private Company
  • Representation of Physical Rehabilitation Network (PRN), a privately held physical therapy care provider and comprehensive practice management organization, in its acquisition of three physical therapy clinics in California.

    We represented Physical Rehabilitation Network (PRN), a privately held physical therapy care provider and comprehensive practice management organization, in its...